On failure to comply with the requirements of the Regulations on Admitting Financial Instruments to Trading (EGRX)
Herewith ITS Ltd. informs that in relation to the below qualified investments there is a non-compliance with the requirements of the Regulations on Admitting Financial Instruments to Trading:
|
No |
Issuer`s Full Name |
Security Kind |
Security Category and Type |
Identification code |
ISIN |
Non-compliance |
|
1. |
Eagle Pharmaceuticals, Inc. |
share |
ordinary share |
EGRX |
US2697961082 |
Information is not disclosed by the issuer of the Qualified Investments in a foreign language widely used on the financial market in accordance with the requirements of any Recognised Foreign Exchange where the QI is listed, or admitted to trading (clause 2.5.5 of the Regulations) |
Based on the assumption that this non-compliance can be resolved, ITS Ltd. has determined to grant a grace period until 30.05.2024, and to continue trading in the affected qualified investments during the grace period.